A single centre, open-label, cross-over study of pharmacokinetics comparing topical zinc/clindamycin gel (Zindaclin) and topical clindamycin lotion (Dalacin T) in subjects with mild to moderate acne.

Author: Chassard D, Kanis R, Namour F, Evene E, Ntssikoussalabongui B, Schmitz V

Author affiliation: Aster Cephac, Paris, FranceStrakan Ltd, Buckholm Mill, Galashiels, UK. dchassard@aster-cephac.com

Publication date & source: 2006, J Dermatolog Treat., 17(3):154-7.

Publication type: Randomized Controlled Trial

Zinc/clindamycin gel (Zindaclin 1%) gel, is a new once-daily topical acne treatment (Strakan Ltd) containing clindamycin phosphate equivalent to 1% clindamycin and zinc acetate in a formulation, which leads to a reduced systemic absorption of clindamycin through the skin. The objective of the study was to compare the systemic absorption of clindamycin from zinc/clindamycin gel and clindamycin lotion (Dalacin T topical lotion, Pharmacia Ltd) after repeated twice-daily topical administration for two periods of 5 days with an intervening gap of 2 weeks in 24 subjects with mild to moderate acne. Plasma Cmax, and AUC0-12 of clindamycin measured after single and multiple applications of zinc/clindamycin gel were between 30% and 50% lower than for clindamycin lotion. As zinc/clindamycin gel is a topical treatment for acne, the lower systemic bioavailability may be beneficial because there may be a correspondingly lower risk of systemic events in zinc/clindamycin gel-treated subjects.

Indexes of Skin Care Research Abstracts by Subject Category Most Recent

Web SmartSkinCare.com

Home | About Us | Contact Us | Ask a Question | Resources

Copyright © 1999-2008 by Dr. G. Todorov / SmartSkinCare.com
Site Disclaimer | Copyright Certification